Search

Your search keyword '"Clerico M."' showing total 456 results

Search Constraints

Start Over You searched for: Author "Clerico M." Remove constraint Author: "Clerico M."
456 results on '"Clerico M."'

Search Results

1. Do patients’ and referral centers’ characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register

2. Sexual dysfunction in multiple sclerosis: the impact of different MSISQ-19 cut-offs on prevalence and associated risk factors

5. Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register

6. Fertility concerns, preservation strategies and quality of life in young women with breast cancer: Baseline results from an ongoing prospective cohort study in selected European Centers

9. Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register

10. Signs and symptoms of COVID-19 in patients with multiple sclerosis

11. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register

12. Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail

13. P1175: REAL LIFE OUTCOMES OF RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: A SINGLE CENTRE EXPERIENCE

14. P1098: OUTCOME OF FOLLICULAR LYMPHOMA PATIENTS IN MAINTENANCE TREATMENT WITH ANTICD20 MONOCLONAL ANTIBODIES IN SARS-COV2 ERA: RESULTS FROM A MULTICENTER, RETROSPECTIVE- PROSPECTIVE ITALIAN STUDY.

15. Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial

16. The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis

17. Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register

18. Signs and symptoms of COVID-19 in patients with multiple sclerosis

19. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

20. Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies

21. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies

22. VENETOCLAX IN MULTI-RELAPSED MANTLE CELL LYMPHOMA PATIENTS: A REAL-LIFE MULTICENTRIC EXPERIENCE

23. The Italian multiple sclerosis register

24. Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment

25. Disease modifying therapies and Covid‐19 severity in Multiple Sclerosis

26. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

27. MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study

30. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme

32. Digital therapeutics in neurology

33. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

34. MRI activity and neutralising antibody as predictos of response to interferon [beta] treatment in multiple sclerosis

35. A combined citizen science-modelling approach for NO2 assessment in Torino urban agglomeration

36. Sex effects across the lifespan in women with multiple sclerosis

37. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register

38. Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?

40. The still under-investigated role of cognitive deficits in PML diagnosis

43. Early weight loss in amyotrophic lateral sclerosis: Outcome relevance and clinical correlates in a population-based cohort

44. Oral Prolonged-Release Oxycodone-Naloxone: Analgesic Response, Safety Profile, and Factors Influencing the Response in Patients With Advanced Cancer

45. Oral prolonged-release Oxycodone-Naloxone: analgesic response, safety profile, and factors influencing the response in advanced cancer patients

46. Effectiveness of Natalizumab on Multiple Sclerosis patients: the Italian registry experience

48. Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis

49. Early diagnosis of progressive multifocal leucoencephalopathy: Longitudinal lesion evolution

50. Fertility concerns, preservation strategies and quality of life in young women with breast cancer: Baseline results from an ongoing prospective cohort study in selected European Centers

Catalog

Books, media, physical & digital resources